Safety and Efficacy of a Sandwich Total Neoadjuvant Therapy Strategy for Low-Risk Distal Locally Advanced Rectal Cancer: Results From the TESS Phase II Trial

Abstract

This prospective phase II multicenter study evaluated a novel sandwich total neoadjuvant treatment (TNT) strategy for patients with relatively low-risk distal locally advanced rectal cancer (LARC). The regimen consisted of two cycles of capecitabine and oxaliplatin (CapeOx) administrated before, during, and after radiotherapy, followed by surgery or a watch-and-wait strategy, and two cycles of adjuvant capecitabine chemotherapy. The primary endpoint was the clinical complete response (cCR) rate. All 98 patients completed radiotherapy, and 88.8% received six cycles of neoadjuvant chemotherapy. In the intention-to-treat analysis, 46.9% of patients achieved cCR, 7.1% achieved near-clinical complete response (near-cCR), and 45.9% had non-clinical complete response (non-cCR). In the observed population, the complete response (CR), pathological complete response (pCR), and sphincter-preservation (SP) rates were 61.2%, 46.4%, and 79.6%, respectively. The local regrowth-free survival, local recurrence-free survival, distant metastases-free survival, and overall survival rates were 89.5%, 100%, 92.9%, and 96.9%, respectively. Overall, this sandwich TNT strategy achieved high rates of cCR, pCR, CR, and SP, with favorable survival outcomes and acceptable toxicity, suggesting a promising organ-preserving treatment approach for selected patients with distal LARC.

Trial Registration: ClinicalTrials.gov identifier: NCT03840239

Keywords

clinical complete response / rectal cancer / sphincter preservation / total neoadjuvant treatment / watch-and-wait strategy

References

[1] J. F. Bosset, L. Collette, G. Calais, et al., “Chemotherapy With Preoperative Radiotherapy in Rectal Cancer,” New England Journal of Medicine 355, no. 11 (2006): 1114–1123.

[2] D. Azria, J. Doyen, M. Jarlier, et al., “Late Toxicities and Clinical Outcome at 5 Years of the ACCORD 12/0405-PRODIGE 02 Trial Comparing Two Neoadjuvant Chemoradiotherapy Regimens for Intermediate-Risk Rectal Cancer,” Annals of Oncology 28, no. 10 (2017): 2436–2442.

[3] W. van Gijn, C. A. Marijnen, I. D. Nagtegaal, et al., “Preoperative Radiotherapy Combined With Total Mesorectal Excision for Resectable Rectal Cancer: 12-Year Follow-up of the Multicentre, Randomised Controlled TME Trial,” The Lancet Oncology 12, no. 6 (2011): 575–582.

[4] A. J. Breugom, W. van Gijn, E. W. Muller, et al., “Adjuvant Chemotherapy for Rectal Cancer Patients Treated With Preoperative (chemo)Radiotherapy and Total Mesorectal Excision: A Dutch Colorectal Cancer Group (DCCG) Randomized Phase III Trial,” Annals of Oncology 26, no. 4 (2015): 696–701.

[5] A. J. Breugom, M. Swets, J. F. Bosset, et al., “Adjuvant Chemotherapy After Preoperative (chemo)Radiotherapy and Surgery for Patients With Rectal Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data,” The Lancet Oncology 16, no. 2 (2015): 200–207.

[6] K. Bujko, R. Glynne-Jones, and M. Bujko, “Does Adjuvant Fluoropyrimidine-Based Chemotherapy Provide a Benefit for Patients With Resected Rectal Cancer Who Have Already Received Neoadjuvant Radiochemotherapy? A Systematic Review of Randomised Trials,” Annals of Oncology 21, no. 9 (2010): 1743–1750.

[7] A. Cercek, C. S. D. Roxburgh, P. Strombom, et al., “Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer,” JAMA Oncology 4, no. 6 (2018): e180071.

[8] M. J. M. van der Valk, C. A. M. Marijnen, B. van Etten, et al., “Compliance and Tolerability of Short-Course Radiotherapy Followed by Preoperative Chemotherapy and Surgery for High-Risk Rectal Cancer—Results of the International Randomized RAPIDO-Trial,” Radiotherapy and Oncology 147 (2020): 75–83.

[9] T. Conroy, P. L. Etienne, E. Rio, et al., “Total Neoadjuvant Therapy With mFOLFIRINOX Versus Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer: 7-Year Results of PRODIGE 23 Phase III Trial, a UNICANCER GI Trial,” Journal of Clinical Oncology 41, no. 17_suppl (2023): LBA3504.

[10] T. Conroy, J. F. Bosset, P. L. Etienne, et al., “Neoadjuvant Chemotherapy With FOLFIRINOX and Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology 22, no. 5 (2021): 702–715.

[11] S. Liu, T. Jiang, L. Xiao, et al., “Total Neoadjuvant Therapy (TNT) Versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis,” The Oncologist 26, no. 9 (2021): e1555–e1566.

[12] J. Jin, Y. Tang, C. Hu, et al., “Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR),” Journal of Clinical Oncology 40, no. 15 (2022): 1681–1692.

[13] M. Maas, R. G. H. Beets-Tan, D. M. J. Lambregts, et al., “Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer,” Journal of Clinical Oncology 29, no. 35 (2011): 4633–4640.

[14] W. Q. Xuan, R. Zhang, X. W. Wei, et al., “The Watch-and-Wait Strategy versus Surgical Resection for Rectal Cancer Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy,” Radiation Oncology 16, no. 1 (2021): 16.

[15] R. K. Smith, R. D. Fry, N. N. Mahmoud, and E. C. Paulson, “Surveillance After Neoadjuvant Therapy in Advanced Rectal Cancer With Complete Clinical Response Can Have Comparable Outcomes to Total Mesorectal Excision,” International Journal of Colorectal Disease 30, no. 6 (2015): 769–774.

[16] D. A. M. Sloothaak, D. E. Geijsen, N. J. van Leersum, et al., “Optimal Time Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Rectal Cancer,” British Journal of Surgery 100, no. 7 (2013): 933–939.

[17] S. W. Mei, Z. Liu, F. Z. Wei, et al., “Impact of Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients,” World Journal of Gastroenterology 26, no. 31 (2020): 4624–4638.

[18] M. Ahmadinejad, A. Parvizi, S. Sheikhi, et al., “Optimal Timing of Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Retrospective Analysis,” European Journal of Surgical Oncology 51, no. 6 (2025): 109702.

[19] C. J. Allegra, G. Yothers, M. J. O'Connell, et al., “Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial,” Journal of the National Cancer Institute 107, no. 11 (2015): djv248.

[20] J. P. Gérard, D. Azria, S. Gourgou-Bourgade, et al., “Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer,” Journal of Clinical Oncology 30, no. 36 (2012): 4558–4565.

[21] C. Aschele, L. Cionini, S. Lonardi, et al., “Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial,” Journal of Clinical Oncology 29, no. 20 (2011): 2773–2780.

[22] Y. H. Gao, X. An, and W. J. Sun, “Evaluation of Capecitabine and Oxaliplatin Administered Prior to and Then Concomitant to Radiotherapy in High Risk Locally Advanced Rectal Cancer,” Journal of Surgical Oncology 109, no. 5 (2014): 478–482.

[23] F. Wang, W. Fan, and J. Peng, “Total Mesorectal Excision With or Without Preoperative Chemoradiotherapy for Resectable Mid/Low Rectal Cancer: A Long-Term Analysis of a Prospective, Single-Center, Randomized Trial,” Cancer Communications 38, no. 1 (2018): 73.

[24] Y. H. Gao, J. Z. Lin, X. An, et al., “Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial,” International Journal of Radiation Oncology Biology Physics 90, no. 5 (2014): 1153–1160.

[25] E. Fokas, M. Allgäuer, B. Polat, et al., “Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12,” Journal of Clinical Oncology 37, no. 34 (2019): 3212–3222.

[26] E. Fokas, A. Schlenska-Lange, B. Polat, et al., “Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-Term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial,” JAMA Oncology 8, no. 1 (2022): e215445.

[27] C. Rödel, U. Graeven, R. Fietkau, et al., “Oxaliplatin Added to Fluorouracil-Based Preoperative Chemoradiotherapy and Postoperative Chemotherapy of Locally Advanced Rectal Cancer (the German CAO/ARO/AIO-04 study): Final Results of the Multicentre, Open-Label, Randomised, Phase 3 Trial,” The Lancet Oncology 16, no. 8 (2015): 979–989.

[28] Y. Deng, P. Chi, P. Lan, et al., “Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial,” Journal of Clinical Oncology 34, no. 27 (2016): 3300–3307.

[29] R. Wang, W. Dai, J. Gong, et al., “Development of a Novel Combined Nomogram Model Integrating Deep Learning-Pathomics, Radiomics and Immunoscore to Predict Postoperative Outcome of Colorectal Cancer Lung Metastasis Patients,” Journal of Hematology & Oncology 15, no. 1 (2022): 11.

[30] M. Bilal, Y. W. Tsang, M. Ali, et al., “Development and Validation of Artificial Intelligence-Based Prescreening of Large-Bowel Biopsies Taken in the UK and Portugal: A Retrospective Cohort Study,” Lancet Digital Health 5, no. 11 (2023): e786–e797.

[31] R. Yamashita, J. Long, T. Longacre, et al., “Deep Learning Model for the Prediction of Microsatellite Instability in Colorectal Cancer: A Diagnostic Study,” The Lancet Oncology 22, no. 1 (2021): 132–141.

[32] M. Bilal, S. E. A. Raza, A. Azam, et al., “Development and Validation of a Weakly Supervised Deep Learning Framework to Predict the Status of Molecular Pathways and Key Mutations in Colorectal Cancer From Routine Histology Images: A Retrospective Study,” Lancet Digital Health 3, no. 12 (2021): e763–e772.

[33] F. Zhang, S. Yao, Z. Li, et al., “Predicting Treatment Response to Neoadjuvant Chemoradiotherapy in Local Advanced Rectal Cancer by Biopsy Digital Pathology Image Features,” Clinical and Translational Medicine 10, no. 2 (2020): e110.

[34] W. Jiang, W. J. Mei, S. Y. Xu, et al., “Clinical Actionability of Triaging DNA Mismatch Repair Deficient Colorectal Cancer From Biopsy Samples Using Deep Learning,” EBioMedicine 81 (2022): 104120.

[35] S. Graham, Q. D. Vu, M. Jahanifar, et al., “CoNIC Challenge: Pushing the Frontiers of Nuclear Detection, Segmentation, Classification and Counting,” Medical Image Analysis 92 (2024): 103047.

[36] R. R. Bahadoer, E. A. Dijkstra, B. van Etten, et al., “Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology 22, no. 1 (2021): 29–42.

[37] E. A. Dijkstra, P. J. Nilsson, G. A. P. Hospers, et al., “Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-Course Chemoradiotherapy and Surgery: A 5-Year Follow-Up of the RAPIDO Trial,” Annals of Surgery 278, no. 4 (2023): e766–e772.

[38] J. Garcia-Aguilar, S. Patil, M. J. Gollub, et al., “Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy,” Journal of Clinical Oncology 40, no. 23 (2022): 2546–2556.

[39] H. M. Thompson, D. M. Omer, S. Lin, et al., “Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial,” JAMA Network Open 7, no. 1 (2024): e2350903.

[40] M. J. M. van der Valk, D. E. Hilling, E. Bastiaannet, et al., “Long-Term Outcomes of Clinical Complete Responders After Neoadjuvant Treatment for Rectal Cancer in the International Watch & Wait Database (IWWD): An International Multicentre Registry Study,” The Lancet 391, no. 10139 (2018): 2537–2545.

[41] A. G. Renehan, L. Malcomson, R. Emsley, et al., “Watch-and-Wait Approach Versus Surgical Resection After Chemoradiotherapy for Patients With Rectal Cancer (the OnCoRe Project): A Propensity-Score Matched Cohort Analysis,” The Lancet Oncology 17, no. 2 (2016): 174–183.

[42] A. L. Appelt, J. Pløen, H. Harling, et al., “High-Dose Chemoradiotherapy and Watchful Waiting for Distal Rectal Cancer: A Prospective Observational Study,” The Lancet Oncology 16, no. 8 (2015): 919–927.

[43] Q. X. Wang, S. Zhang, W. W. Xiao, et al., “High Dose Chemoradiotherapy Increases Chance of Organ Preservation With Satisfactory Functional Outcome for Rectal Cancer,” Radiation Oncology 17, no. 1 (2022): 98.

[44] D. Baron, T. P. Loscos, R. Schiappa, et al., “A Phase III Randomised Trial on the Addition of a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemo-Radiotherapy for Organ Preservation in Early Rectal Adenocarcinoma: 5 Year Results of the OPERA Trial,” Annals of Oncology 36, no. 2 (2025): 208–215.

[45] D. T. Arp, A. L. Appelt, L. H. Jensen, et al., “Treatment Planning for Patients With Low Rectal Cancer in a Multicenter Prospective Organ Preservation Study,” Physica Medica 118 (2024): 103206.

[46] L. H. Jensen, S. Risum, J. D. Nielsen, et al., “Curative Chemoradiation for Low Rectal Cancer: Primary Clinical Outcomes From a Multicenter Phase II Trial,” Journal of Clinical Oncology 40, no. 17_suppl (2022): LBA3514.

[47] W. W. Xiao, G. Chen, Y. H. Gao, et al., “Effect of Neoadjuvant Chemoradiotherapy With or Without PD-1 Antibody Sintilimab in pMMR Locally Advanced Rectal Cancer: A Randomized Clinical Trial,” Cancer Cell 42, no. 9 (2024): 1570–1581.e4.

[48] Z. Y. Lin, P. Zhang, P. Chi, et al., “Neoadjuvant Short-Course Radiotherapy Followed by Camrelizumab and Chemotherapy in Locally Advanced Rectal Cancer (UNION): Early Outcomes of a Multicenter Randomized Phase III Trial,” Annals of Oncology 35, no. 10 (2024): 882–891.

[49] F. Xia, Y. Wang, H. Wang, et al., “Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH),” Journal of Clinical Oncology 42, no. 28 (2024): 3308–3318.

[50] X. Wang, P. Liu, Y. Xiao, et al., “Total Neoadjuvant Treatment With Long-Course Radiotherapy versus Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors (TNTCRT): A Multicenter, Randomized, Open-Label, Phase 3 Trial,” Journal of Clinical Oncology 42, no. 17_suppl (2024): LBA3511.

[51] M. L. Wikberg, A. Ling, X. Li, Å. Öberg, S. Edin, and R. Palmqvist, “Neutrophil Infiltration is a Favorable Prognostic Factor in Early Stages of Colon Cancer,” Human Pathology 68 (2017): 193–202.

[52] S. Lai, X. Lou, X. Fan, et al., “Density and Distribution of Lymphocytes in Pretherapeutic Rectal Cancer and Response to Neoadjuvant Therapy,” Gastroenterology Report (Oxford) 8, no. 6 (2020): 445–452.

[53] M. R. Galdiero, P. Bianchi, F. Grizzi, et al., “Occurrence and Significance of Tumor-Associated Neutrophils in Patients With Colorectal Cancer,” International Journal of Cancer 139, no. 2 (2016): 446–456.

[54] V. Governa, E. Trella, V. Mele, et al., “The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer,” Clinical Cancer Research 23, no. 14 (2017): 3847–3858.

[55] H. Peng, X. Wu, S. Liu, et al., “Multiplex Immunofluorescence and Single-Cell Transcriptomic Profiling Reveal the Spatial Cell Interaction Networks in the Non-Small Cell Lung Cancer Microenvironment,” Clinical and Translational Medicine 13, no. 1 (2023): e1155.

[56] W. Xiao, Total Neoadjuvant Treatment to Increase the Clinical Complete Response Rate for diStal Locally Advanced Rectal Cancer (TESS), ClinicalTrials.gov identifier: NCT03840239 (2022).

[57] S. Liu, X. Wang, Y. Zhuang, et al., “Total Neoadjuvant Treatment to Increase the Clinical Complete Response Rate for Distal Locally Advanced Rectal Cancer (TESS): A Study Protocol of a Prospective, Open-Label, Multicenter, Single-Arm, Phase 2 Trial,” Cancer Medicine 12, no. 12 (2023): 13352–13360.

[58] Y. Zhou, Q. Dou, H. Chen, J. Qin, and P. A. Heng, “SFCN-OPI: Detection and Fine-Grained Classification of Nuclei Using Sibling FCN With Objectness Prior Interaction,” Thirty-Second AAAI Conference on Artificial Intelligence 32, no. 1 (2018): 2652–2659.

[59] J. P. Väyrynen, M. C. Lau, K. Haruki, et al., “Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin-Stained Sections,” Clinical Cancer Research 26, no. 16 (2020): 4326–4338.

[60] H. R. Ali, A. Dariush, E. Provenzano, et al., “Computational Pathology of Pre-Treatment Biopsies Identifies Lymphocyte Density as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer,” Breast Cancer Research 18, no. 1 (2016): 21.

[61] M. Shaban, S. A. Khurram, M. M. Fraz, et al., “A Novel Digital Score for Abundance of Tumour Infiltrating Lymphocytes Predicts Disease Free Survival in Oral Squamous Cell Carcinoma,” Scientific Reports 9 (2019): 13341.

[62] H. Failmezger, S. Muralidhar, A. Rullan, C. E. de Andrea, E. Sahai, and Y. Yuan, “Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology,” Cancer Research 80, no. 5 (2020): 1199–1209.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.